Statement of Changes in Beneficial Ownership (4)
June 11 2020 - 6:58PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
WANG HUIMIN |
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp
[
EW
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CVP, Japan & Intercontinental |
(Last)
(First)
(Middle)
ONE EDWARDS WAY |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/11/2020 |
(Street)
IRVINE, CA 92614
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 6/11/2020 | | M(1) | | 11649.0000 | A | $13.9800 | 105953.7768 | D | |
Common Stock | 6/11/2020 | | S(1) | | 84.0000 | D | $72.5900 | 105869.7768 | D | |
Common Stock | 6/11/2020 | | S(1) | | 3287.0000 | D | $72.4227 (2) | 102582.7768 | D | |
Common Stock | 6/11/2020 | | S(1) | | 8362.0000 | D | $71.2500 (3) | 94220.7768 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option (Right to Acquire) | $13.9800 | 6/11/2020 | | M (1) | | | 11649.0000 | 5/8/2015 | 5/7/2021 | Common Stock | 11649.0000 | $0.0000 | 93204.0000 | D | |
Explanation of Responses: |
(1) | The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. |
(2) | This transaction was executed in multiple trades at prices ranging from $71.90 to $72.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. |
(3) | This transaction was executed in multiple trades at prices ranging from $70.88 to $71.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Remarks: On May 29, 2020, the common stock of Edwards Lifesciences Corporation split 3-for-1, resulting in the reporting person's ownership of additional shares of common stock and stock options. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
WANG HUIMIN ONE EDWARDS WAY IRVINE, CA 92614 |
|
| CVP, Japan & Intercontinental |
|
Signatures
|
Linda J. Park, Attorney-in-Fact | | 6/11/2020 |
**Signature of Reporting Person | Date |
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Sep 2023 to Sep 2024